Evidence map›Paper›PMID 42734504›Full record

ArticleJournal of chemical information and modeling2026

In Silico Decoding of Nonsteroidal Mineralocorticoid Receptor Antagonist Binding: Implications for Drug Design.

Felipe Pérez-Gordillo, Laureano E Carpio, Diego Alvarez de la Rosa, Mercedes Martín-Martínez

Abstract read
In one paragraph

Article in Journal of chemical information and modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Felipe Pérez-GordilloInstituto de Química Médica (IQM-CSIC), Juan de la Cierva 6, Madrid28006, Spain.
Laureano E CarpioMolDrug AI Systems SL, Parque Tecnológico de Valencia, Valencia46980, Spain.
Diego Alvarez de la RosaUniversidad de La Laguna , La Laguna382000, Spain.ORCID 0000-0002-4324-2793
Mercedes Martín-MartínezInstituto de Química Médica (IQM-CSIC), Juan de la Cierva 6, Madrid28006, Spain.ORCID 0000-0002-6449-0905

Funding

Consejo Superior de Investigaciones Cient?ficas 202580E109European Regional Development Fund NAMinisterio de Ciencia, Innovaci?n y Universidades PID2021-126423OB-C22Ministerio de Ciencia, Innovaci?n y Universidades PID2022-138788NB-I00Ministerio de Ciencia, Innovaci?n y Universidades PID2024-160392OB-C22
6 · The paper itself

Abstract

The mineralocorticoid receptor (MR), a member of the steroid hormone nuclear receptor subfamily, mediates the effects of aldosterone and glucocorticoids. Initially characterized in epithelial tissues as a key regulator of blood pressure, MR was later found to be widely expressed across multiple tissues, where it mediates processes such as inflammation, oxidative stress, and fibrosis. Accordingly, MR antagonists (MRAs) have important clinical applications beyond their diuretic effect, forming a cornerstone in the treatment of chronic heart failure and showing promise in conditions like diabetic nephropathy. Nonsteroidal MRAs typically show fewer off-target effects than their steroidal counterparts, although the risk of hyperkalemia─especially in patients with renal impairment─remains a concern. A detailed understanding of MRA-binding modes is therefore crucial for the development of improved therapeutics. To this end, we conducted an extensive computational study integrating induced fit docking (IFD) and molecular dynamics (MD) simulations across a comprehensive set of MRAs. This approach highlights key interactions responsible for binding affinity and offers insights into the molecular basis of selectivity and antagonism. Moreover, MD simulations revealed a potential link between the ligand interaction with Trp806 and coregulator recruitment. These findings provide a valuable foundation for in silico rational design of next-generation MRAs with enhanced safety and efficacy profiles.

Indexed as

Drug DesignMineralocorticoid Receptor AntagonistsReceptors, MineralocorticoidBinding SitesHumansMolecular Docking SimulationMolecular Dynamics SimulationProtein BindingMineralocorticoid Receptor AntagonistsReceptors, Mineralocorticoid

Identifiers

PMID42734504
PMCPMC13580125

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.